[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07947]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness 
Consortium

    Notice is hereby given that, on January 5, 2024, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical 
Manufacturing Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed 
written notifications simultaneously with the Attorney General and the 
Federal Trade Commission disclosing (1) the identities of the parties 
to the venture and (2) the nature and objectives of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture as of the date of this filing are: Advanced BioSciences 
Laboratory, Inc., Rockville, MD; Antheia, Inc., Menlo Park, CA; ApiJect 
Systems America, Inc., Stamford, CT; Applied Materials, Inc., Santa 
Clara, CA; CAMRIS International LLC, Bethesda, MD; Civica, Inc., Lehi, 
UT; Clarivate Analytics (US) LLC, Ann Arbor, MI; Ginkgo Bioworks, Inc., 
Boston, MA; Global Life Sciences Solutions USA LLC dba Cytiva, 
Marlborough, MA; Grand River Aseptic Manufacturing, Inc., Grand Rapids, 
MI; ImmunityBio, Inc., Culver City, CA; Joint Research and Development 
(JRAD) LLC, Stafford, VA; Maravai LifeSciences, San Diego, CA; Mission 
Pharmacal Company, San Antonio, TX; NextBeam LLC, North Sioux City, SD; 
Northeastern University, Boston, MA; OCUGEN, Inc., MALVERN, PA; Ocyon 
Bio PR, Inc., Aguadilla, PUERTO RICO; PSC Biotech Corp., Pomona, CA; 
Regis Technologies, Inc., Morton Grove, IL; Resilience Government 
Services, Alachua, FL; Riya Interactive, Inc., Chicago, IL; SEQENS, 
Devens, MA; Sanofi Pasteur, Inc., Swiftwater, PA; Slingshot 
Biosciences, Inc., Emeryville, CA; Smart World LLC dba Steri-Tek, 
Fremont, CA; TR Processing LLC, Golden Valley, MN; The Conafay Group, 
Washington, DC; USAntibiotics LLC, Bristol, TN; Varda Space Industries, 
Inc., El Segundo, CA.
    Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the general 
areas of BioMaP Consortium's planned activities are to engage the 
biopharmaceutical industrial base to enable targeted development 
expertise, address new and emerging biopharmaceutical technologies that 
enhance existing capabilities, as well as prepare for potential 
response to emerging pathogens with pandemic potential.

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07947 Filed 4-15-24; 8:45 am]
BILLING CODE P